Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease

American Journal of Gastroenterology

Volumn 98, Issue 3 SUPPL., 2003, Pages

  Quigley, Eamonn M M ^a  

^a University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; CLINICAL FEATURE; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; ENDOSCOPY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LONG TERM CARE; PALLIATIVE THERAPY; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; SHORT COURSE THERAPY; SYMPTOM; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0037343934     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(03)00012-1     Document Type: Conference Paper

References (75)

1. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):24-9.
2. Smout AJPM. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 1997;11(suppl 2):81-5.
3. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
4. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol 2001;96:303-14.
5. Quigley EMM, DiBaise JK. Non-erosive reflux disease: the real problem in gastro-oesophageal reflux disease. Dig Liver Dis 2001;33:523-7.
6. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-24.
7. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-esophageal reflux disease. Lancet 1990;335:205-8.
8. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop Report. Gut 1999;44(suppl 2):S1-16.
9. DiBaise JK, Lof J, Quigley EMM. Can symptoms predict esophageal motor function or acid exposure in gastroesophageal reflux disease? A comparison of esophageal manometric and twenty-four-hour pH parameters in typical and extraesophageal gastroesophageal reflux disease. J Clin Gastroenterol 2001;32:128-32.
10. Richter JE. Extraesophageal presentations of gastroesophageal reflux disease. Semin Gastrointest Dis 1997;8:75-89.
11. Wong RKH, Hanson DG, Waring PJ, Shaw G. ENT manifestations of gastroesophageal reflux. Am J Gastroenterol 2000;95(suppl):S16-22.
12. DiBaise JK, Olusola BF, Huerter JV, Quigley EMM. Role of GERD in chronic recurrent sinusitis: a prospective, open label, pilot trial. Am J Gastroenterol 2002;97:843-50.
13. DeVault KR. Overview of therapy for the extraesophageal manifestations of gastroesophageal reflux disease. Am J Gastroenterol 2000;95(suppl):S39-44.
14. Bate CM, Griffin SM, Keeling PWN, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-55.
15. Quigley EMM. Non-erosive reflux disease (NERD): part of the spectrum of gastro-oesophageal reflux, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001;13(suppl 1):S13-8.
16. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65.
17. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal disease. Scand J Gastroenterol 1998;33:1023-9.
18. Talley NJ, Colin-Jones D, Koch K, et al. Functional gastroduodenal disorders. Gut 1999;45(suppl 11):1137-42.
19. Galmiche JP, Barthelmy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
20. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy-negative reflux disease (Cochrane Review). In: The Cochrane Library, Issue 4, 2000.
21. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000;160:1810-6.
22. Bate CM, Green JRB, Axon ATR, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastrooesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997;11:755-63.
23. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
24. Kahrilas PJ, Miner PB, Johanson JJ, et al. Efficacy of rabeprazole in endoscopically negative GERD patients with frequent moderate to severe heartburn symptoms (abstract). Gastroenterology 2002;122(suppl):S1280.
25. Sontag SJ, Hirschowitz BI, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U. S. multicenter study. Gastroenterology 1992;102:109-18.
26. Farley A, Wruble LD, Humphries TJ, for the Rabeprazole Study Group. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Am J Gastroenterol 2000;95:1894-9.
27. Drossman DA. Importance of the psyche in heartburn and dyspepsia. Aliment Pharmacol Ther 1997;11(suppl 2):57-67.
28. Campos GMR, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999;3:292-300.
29. Eubanks TR, Omelanczuk P, Richards C, et al. Outcomes of laparoscopic antireflux procedures. Am J Surg 2000;179:391-5.
30. Vu MK, Straathof JWA, van der Schaar PJ, et al. Motor and sensory function of the proximal stomach in reflux disease and after laparoscopic Nissen fundoplication. Am J Gastroenterol 1999;94:1481-89.
31. Vu MK, Ringers J, Arndt JW, et al. Prospective study of the effect of laparoscopic hemifundoplication on motor and sensory function of the proximal stomach. Br J Surg 2000;87:338-43.
32. Quigley EMM. Motility, heartburn and dyspepsia. Aliment Pharmacol Ther 1997;11(suppl 2):41-50.
33. Bais JE, Samsom M, Boudesteijn EA, et al. Impact of delayed gastric emptying on the outcome of antireflux surgery. Ann Surg 2001;234:139-46.
34. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998;93:1028-32.
35. Moss SF, Bardhan KD, Quigley EMM, et al. Barrett's oesophagus - current status, future challenges. Available at www. gastrohep.com/freespeech/freespeech.asp?id = 39.
36. Quigley EMM. Gastro-oesophageal reflux disease - spectrum or continuum? G J Med 1997;90:75-8.
37. Cameron AJ, Lagergren J, Henriksson C, et al. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002;122:55-9.
38. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
39. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal carcinoma. Ann Intern Med 2000;133:165-75.
40. Lagergren J, Bergstrom R, Nyren O. Association between body mass index and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
41. Ye W, Chow W-H, Lagergren J, et al. Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001;121:1286-93.
42. Srinivasan R, Katz PO, Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 2001;15:519-24.
43. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-5.
44. Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001;96:1711-7.
45. Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Hiatal hernia and acid reflux frequency predict presence and length of Barrett's esophagus. Dig Dis Sci 2002;47:256-64.
46. O'Boyle CJ, Watson DI, DeBeaux AC, Jamieson GG. Preoperative predication of long-term outcome following laparoscopic fundoplication. ANZ J Surg 2002;72:471-5.
47. Deviere J, Pastorelli A, Louis H, et al. Endoscopic implantation of a polymer in the lower esophageal sphincter for gastroesophageal reflux: a pilot study. Gastrointest Endosc 2002;55:335-41.
48. Triadafilopoulos G, DiBaise JK, Nostrant TT, et al. Radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD. Gastrointest Endosc 2001;53:407-515.
49. Filipi CJ, Lehman GA, Rothstein RI, et al. Transoral, flexible endoscopic suturing for the treatment of GERD. a multicenter trial. Gastrointest Endosc 2001;53:416-22.
50. DiBaise JK, Brand RE, Quigley EMM. Endoluminal delivery of radiofrequency energy to the gastroesophageal junction in uncomplicated GERD: efficacy and potential mechanism of action. Am J Gastroenterol 2002;97:833-42.
51. Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 2001;53:559-65.
52. Tam W, Edebo A, Bruno M, et al. Endoscopy-negative reflux disease (ENRD): high-resolution endoscopic and histological signs (abstract). Gastroenterology 2002;122:A628.
53. Watson RGP, Tham TCK, Johnston BT, McDougall NI. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive oesophagus." Gut 1997;40:587-90.
54. Johnston BT, Lewis SA, Collins JS, et al. Acid perception in gastro-oesophageal reflux disease is dependent on psychosocial factors. Scand J Gastroenterol 1995;30:1-5.
55. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. Gut 1999;45(suppl 2):1131-6.
56. Vaz Coelho LG, Leon-Barua R, Quigley EMM. Latin-American consensus conference on Helicobacter pylori infection. Am J Gastroenterol 2000;95:2688-91.
57. Moraes-Filho JPP, Cecconello I, Gama-Rodrigues, et al., and the Brazilian Consensus Group. Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management. Am J Gastroenterol 2002;97:241-8.
58. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998;115:42-9.
59. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the "omeprazole test" in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999;159:2161-8.
60. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991;32:845-8.
61. Schindlbeck NE, Klauser AG, Berghammer G, et al. Three-year follow-up of patients with gastro-oesophageal reflux disease. Gut 1992;33:1016-9.
62. Ollyo JB, Monnier P, Fontolliet C, Savary M. The natural history, prevalence and incidence of reflux oesophagitis. Gullet 1993;3(suppl):3-10.
63. Kuster E, Ros E, Toledo-Pimentel V, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994;35:8-14.
64. Trimble KC, Douglas S, Pryde A, Heading RC. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995;40:1098-1104.
65. McDougall NI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10 year follow up on patient symptomatology and quality of life. Gut 1996;38:481-6.
66. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997;92:37-41.
67. McDougall NI, Johnston BT, Collins JS, et al. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol 1997;9:1161-7.
68. McDougall NI, Johnston BT, Collins JS, et al. Three to 4.5 year prospective study of prognostic indicators in gastrooesophageal reflux disease. Scand J Gastroenterol 1998;33:1016-22.
69. Glise H. Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol 1995;30(suppl 210):38-42.
70. Wiklund I. Quality of life in patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96(suppl):S46-53.
71. Tew S, Jamieson GG, Pilowsky I, et al. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus 1997;10:9-15.
72. Bardhan KD, Muller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. Br Med J 1999;318:502-7.
73. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
74. Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis - effects of treatment with omeprazole. Am J Gastrenterol 1999;94:1782-9.
75. Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001;13(suppl 1):S19-22.